PI3K inhibitor treatment ameliorates the glucocorticoid insensitivity of PBMCs in severe asthma

This study demonstrates that PI3K inhibitors ameliorate GC insensitivity in severe asthma by restoring HDAC2 activity and inhibiting the phosphorylation of nuclear signaling transcription factors.